Effects of Momordica charantiaon pancreatic histopathological changes associated with streptozotocin-induced diabetes in neonatal rats

Histology and Histopathology

Volumn 26, Issue 1, 2011, Pages 13-21

  Abdollahi, M ^a   Zuki, A B Z ^a   Goh, Y M ^a   Rezaeizadeh, A ^a   Noordin, M M ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

cells; Diabetes; Momordica charantia; Neonatal rats; Pancreas; Streptozotocin

Indexed keywords

ANIMALIA; MOMORDICA; MOMORDICA CHARANTIA; RATTUS;

ANTIDIABETIC AGENT; GLIBENCLAMIDE; INSULIN; PLANT EXTRACT;

ANIMAL; ARTICLE; BLOOD; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FRUIT; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; METABOLISM; MOMORDICA CHARANTIA; NEWBORN; ORAL DRUG ADMINISTRATION; PANCREAS; PANCREAS ISLET BETA CELL; PATHOLOGY; PHYTOTHERAPY; RAT; SPRAGUE DAWLEY RAT; TRANSMISSION ELECTRON MICROSCOPY;

ADMINISTRATION, ORAL; ANIMALS; ANIMALS, NEWBORN; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; FRUIT; GLYBURIDE; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INSULIN; INSULIN-SECRETING CELLS; MICROSCOPY, ELECTRON, TRANSMISSION; MOMORDICA CHARANTIA; PANCREAS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78651228900     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ahmad N., Hassan M. R., Halder H. and Bennoor K. S. (1999). Effects of Momordica charantia (Karolla) extracts on fasting and postprandial serum glucose levels in NIDDM patients. Bangladesh Med. Res. Counc. Bull. 25, 11-13.
2. Ahmed I., Adeghate E., Sharma A. K., Pallot D. J. and Singh J. (1998). Effects of Momordica charantia fruit juice on islet morphology in the pancreas of streptozotocin-diabetic rats. Diabetes Res. Clin. Pract. 40, 145-151.
3. Ahmed I., Adeghate E., Cummings E., Sharma A. and Singh J. (2004). Beneficial effects and mechanism of action of Momordica charantia juice in the treatment of streptozotocin-induced diabetes mellitus in rats. Mol. Cell. Biol. 261, 63-70.
4. Anello M., Lupi R., Spampinato D., Piro S., Masini M., Boggi U., Del Prato S., Rabuazzo A. M., Purrello F., Marchetti P. (2005). Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients. Diabetologia 48, 282-289.
5. Baynes J. W. and Thorpe S. R. (1999). Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48, 1-9.
6. Bruin J. E., Gerstein H. C., Morrison K. M. and Holloway A. C. (2008). Increased pancreatic beta-cell apoptosis following foetal and neonatal exposure to nicotine is mediated via the mitochondria. Toxicol. Sci. 103, 362-370.
7. Cemek M., Kaǧa S., Simşek N., Büyükokuroǧ lu M. E. and Konuk M. (2008). Antihyperglycemic and antioxidative potential of Matricaria chamomilla L. in streptozotocin-induced diabetic rats. J. Nat. Med. 62, 284-293.
8. Chen Q., Chan L. L. Y. and Li E. T. S. (2003). Bitter melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J. Nutr. 133, 1088-1093.
9. Degirmenci I., Ustuner M. C., Kalender Y., Kalender S. and Gunes H. V. (2005). The effects of acarbose and Rumex patientia L. on ultrastructural and biochemical changes of pancreatic B cells in streptozotocin-induced diabetic rats. J. Ethnopharmacol. 97, 555-559.
10. Fernandes N. P., Lagishetty C. V., Panda V. S. and Naik S. R. (2007). An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC. Complement Altern. Med. 7, 29.
11. Garau C., Singh J. and Cummings E. (2003). Beneficial effects and mechanism of action of Momordica charantia in the treatment of diabetes mellitus: a mini review. Int. J. Diabetes Metabol. 11, 46-55.
12. Grover J. K. and Yadav S. P. (2004). Pharmacological actions and potential uses of Momordica charantia: a review. J. Ethnopharmacol. 93, 123-132.
13. Hardt P. D., Killinger A., Nalop J., Schnell-Kretschmer H., Zekorn T. and Klör H. U. (2002). Chronic pancreatitis and Diabetes mellitus. Pancreatology. 2, 30-33.
14. Hribal M. L., D'Alfonso R., Giovannone B., Lauro D., Liu Y. Y., Borboni P., Federici M., Lauro R. and Sesti G. (2001). The sulfonylurea glimepiride regulates intracellular routing of the insulin-receptor complexes through their interaction with specific protein kinase C isoforms. Mol. Pharmacol. 59, 322-330.
15. Kim J. D., Kang S. M., Seo B. I., Choi H. Y., Choi H. S. and Ku S. K. (2006). Anti-diabetic activity of SMK001, a poly herbal formula in streptozotocin induced diabetic rats: therapeutic study. Biol. Pharm. Bull. 29, 477-482.
16. Krawinkel M. B. and Keding G. B. (2006). Bitter gourd (Momordica charantia): A dietary approach to hyperglycemia. Nutr. Rev. 64, 331-337.
17. Kumar G., Shetty A. and Salimath P. (2008). Modulatory effect of bitter gourd (M omordica charantia LINN.) on alterations in kidney heparan sulfate in streptozotocin-induced diabetic rats. J. Ethnopharmacol. 115, 276-283.
18. Leonardi O., Mints G., and Hussain M. A. (2003). Beta-cell apoptosis in the pathogenesis of human type 2 diabetes mellitus. Eur. J. Endocrinol. 149, 99-102.
19. Li L., Yi Z., Seno M. and Kojima I. (2004). Activin A and betacellulin: effect on regeneration of pancreatic beta-cells in neonatal streptozotocin- treated rats. Diabetes 53, 608-615
20. Lupi R. and Del Prato S. (2008). [beta]-cell apoptosis in type 2 diabetes: quantitative and functional consequences. Diabetes and Metab. 34, S56-S64.
21. Mahomoodally M. F., Gurib-Fakim A. and Subratty A. H. (2007). Effect of exogenous ATP on Momordica charantia Linn. (Cucurbitaceae) induced inhibition of D-glucose, L-tyrosine and fluid transport across rat everted intestinal sacs in vitro. J. Ethnopharmacol. 110, 257-263.
22. McCarty M. F. (2004). Does bitter melon contain an activator of AMP-activated kinas? Med. Hypotheses. 63, 340-343.
23. Miura T., Itoh C., Iwamoto N., Kato M., Kawai M., Park S. R. and Suzuki I. (2001). Hypoglycemic activity of the fruit of the Momordica charantia in type 2 diabetic mice. J. Nutr. Sci. Vitaminol. 47, 340-344.
24. Nivitabishekam S. N., Asad M. and Prasad V. S. (2009). Pharmacodynamic interaction of Momordica charantia with rosiglitazone in rats. Chem. Biol. Interact. 177, 247-253.
25. Pari L. and Ashokkumar N. (2005). Effect of N-benzoyl-D-phenylalanine, a new potential oral antidiabetic agent, in neonatal streptozotocininduced diabetes in rats. Pharmacol. Rep. 57, 498-503.
26. Poitout V. and Robertson R. P. (2002). Minireview: Secondary ß-cell failure in type 2 diabetes-A convergence of glucotoxicity and lipotoxicity. J. Endocrinol. 143, 339-342.
27. Portha B., Movassat J., Cuzin-Tourrel C., Bailbe D., Giroix M. H., Serradas P., Dolz M. and Kergoat M. (2007). Neonatally streptozotocin-induced (n-STZ) diabetic rats: A family of type 2 diabetes models. In: Animal models of diabetes: Frontiers in research. Shafrir E. (ed). CRC Press. New York. pp 223-250
28. Prentki M., Jol E., El-Assaad W. and Roduit R. (2002). Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: Role in B-cell adaptation and failure in the etiology of diabetes. Diabetes 51, 405S-413.
29. Rahier J., Guiot Y., Goebbels R. M., Sempoux C. and Henquin J. C. (2008). Pancreatic B-cell mass in European subjects with type 2 diabetes. Diabetes Obes. Metab. 10, 32-42.
30. Robertson R. P., Harmon J., Tran P. O., Tanaka Y. and Takahashi H. (2003). Glucose Toxicity in ß-Cells: Type 2 Diabetes, Good Radicals Gone Bad, and the Glutathione Connection. Diabetes 52, 581-587.
31. Sakamoto K., Yonoki Y., Fujioka T., Matsumura M., Mitsuta Y., Sano M., Saito M., Nakahara T. and Ishii K. (2006). Disappearance of glibenclamide- induced hypoglycemia in Wistar-Kyoto rats. Biol. Pharm. Bull. 29, 574-576.
32. Sathishsekar D. and Subramanian S. (2005). Beneficial effects of Momordica charantia seeds in the treatment of STZ-induced diabetes in experimental rats. Biol. Pharm. Bull. 28, 978-983.
33. Shih C., Lin C., Lin W. and Wu J. (2009). Momordica charantiaextract on insulin resistance and the skeletal muscle GLUT4 protein in fructose-fed rats. J. Ethnopharmacol. 123, 82-90.
34. Sitasawad S. (2000). Role of bittergourd fruit juice in STZ-induced diabetic state in vivoand in vitro. J. Ethnopharmacol. 73, 71-79.
35. Shulman G. I. (2000). Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171-176.
36. Sridhar M. G., Vinayagamoorthi R., Arul Suyambunathan V., Bobby Z. and Selvaraj N. (2008). Bitter gourd (Momordica charantia) improves insulin sensitivity by increasing skeletal muscle insulin-stimulated IRS-1 tyrosine phosphorylation in high-fat-fed rats. Brit. J. Nutr. 99, 806-812.
37. Soltani N., Keshavarz M., Minaii B., Mirershadi F., Asl S. Z. and Dehpour A. R. (2005). Effect of administration of oral magnesium on plasma glucose and pathological changes in the aorta and pancreas of diabetic rats. Clin. Exp. Pharmacol. Physiol. 32, 604-610.
38. Suzuki H., Fukushima M., Usami M., Ikeda M., Taniguchi A., Nakai Y., Matsuura T., Kuroe A., Yasuda K., Kurose T., Seino Y. and Yamada Y. (2003). Factors responsible for development from normal glucose tolerance to isolated postchallenge hyperglycemia. Diabetes Care 26, 1211-1215.
39. Takada J., Machado M. A., Peres S. B., Brito L. C., Borges-Silva C. N., Costa C. E. M., Fonseca-Alaniz M. H., Andreotti S. and Lima F. (2007). Neonatal streptozotocin-induced diabetes mellitus: a model of insulin resistance associated with loss of adipose mass. Metab. Clin. Exp. 56, 977-984.
40. Virdi J., Sivakami S., Shahani S., Suthar A. C., Banavalikar M. M. and Biyani M. K. (2003). Antihyperglycemic effects of three extracts from Momordica charantia. J. Ethnopharmacol. 88, 107-111.
41. Welihinda J., Karunanayake E. H., Sheriff M. H. and Jayasinghe K. S. (1986). Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J. Ethnopharmacol. 17, 277-282.
42. Wu S. and Ng L. (2008). Antioxidant and free radical scavenging activities of wild bitter melon (Momordica charantia Linn. var. abbreviata Ser.) in Taiwan. LWT Food Sci. Technol. 41, 323-330.